恶性黑色素瘤讲课.pptVIP

恶性黑色素瘤 2012年进修生讲课;恶性黑色素瘤;发病部位;美国发病情况;发病情况;;;病因学;日晒与恶黑发病关系;临床表现;临床分期与预后;;;原发病变预后特征;;;;区域淋巴结转移与预后;;;远处转移与预后;;Survival in Metastatic Melanoma;;恶黑的复发;恶性黑色素瘤的血清学指标 ;恶性黑色素瘤的血清学指标;恶性黑色素瘤的血清学指标;恶性黑色素瘤的血清学指标;手术治疗;;选择性淋巴结清扫术;术后辅助治疗;高危的Ⅱ Ⅲ期恶黑辅助治疗;辅助治疗;ADJUVANT INTERFERON ALFA-2A TREATMENT IN RESECTED PRIMARY STAGE II CUTANEOUS MELANOMA-----AUSTRIAN MALIGNANT MELANOMA COOPERATIVE GROUP. ;Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.;Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial;Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial;Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.;晚期恶黑的治疗;晚期恶黑的治疗 ;化疗和生物治疗;;;化疗;《Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.》;联合化疗;常见化疗方案;Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma ;Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma;Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma;Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) ;Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951);Phase III Multicenter Randomized Trial of the Dartm